NRAS and melanoma: The results, for the first time, introduced the functional axis identified in this analytical study and DMKN linking to ERK/MAPK-initiated signaling pathways as a potential non-invasive biomarker in the various subsets of melanomas, irrespective of EMT and BRAF/NRAS mutation status, along with a relevant regulatory network of the EMT-like program in melanoma cells.